Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis
A legfontosabb adatok
- Ki végzi
- Wake Forest University Health Sciences
- Hol
- Charlotte (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 1/2. fázis
- Kezdés
- 2026. febr.
- Várható befejezés
- 2026. nov.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Amniotic fluid or placental CD117 stem cells
- A regiszteradat frissítve
- 2026. február 6.
- Miért állt le
- lack of funding
Ki vehet részt
- Életkor
- 18 év – 60 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged 18-60 years
- Diagnosed with primary or secondary progressive MS according to the 2017 revised McDonald criteria
- Expanded Disability Status Scale (EDSS) of 3.0 to 8.0 with at least one functional scale that is not vision or sensory or brainstem or cognitive or bowel/bladder that is scoring 3.0 or greater
- Clinically stable as determined by their neurologist for the past 6 months
- On no disease-modifying therapy (DMT) for at least 6 months, or on the same DMT for at least 6 months before study entry
- Can give informed consent
- Women of child-bearing age must practice adequate contraception techniques in the eye of the investigator and continue to do so during the study period
- Must be a good candidate, known for compliance for example, in the opinion of the investigators
Ki nem vehet részt
- Prior organ, tissue, or stem cell transplant or cell therapy within 3 years of study entry
- Severe allergic reactions to any component of the study treatments
- Active infections or malignancies
- History of a malignancy within the past two years except for skin cancer that has been excised and controlled with only surgical treatment, not requiring chemotherapy or radiotherapy
- Any medical condition that the investigator deems as unsuitable with therapy
- A diagnosis of a progressive neurological disorder other than multiple sclerosis
- Inability to have a lumbar puncture, for example severe bleeding diathesis
- The results of the following laboratory results deemed suitable by the investigators: CBC with diff, CMP, INR, aPTT, Hepatitis C serology, HIV serology, RPR
- Participation in another clinical trial within the last 30 days
- Significant comorbidities
- Inability to have an MRI scan
- Pregnant or breastfeeding or intention to become pregnant during the study
Helyszínek itt: Egyesült Államok
- Atrium HealthCharlotte, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
In this clinical trial, researchers are exploring a novel approach to delivering therapy directly into the spinal fluid, which surrounds and nourishes the brain and spinal cord. The study focuses on patients with progressive multiple sclerosis (MS), a form of the disease that leads to worsening disability without the typical relapses seen in other MS subtypes.
A teljes eredeti leírásKevesebb
This investigational therapy involves the use of stem cells derived from amniotic fluid-the protective liquid surrounding a developing baby in the womb. To the best of the researchers' knowledge, these specific stem cells have never been tested in MS patients before. Amniotic fluid is ethically sourced from routine medical procedures during pregnancy, and similar stem cells can also be obtained from placentas that are typically discarded after childbirth.
Participants in the trial will receive multiple injections of these stem cells into their spinal fluid over the course of a year. Researchers will closely monitor for the safety of this therapy, as well as monitor the participants' walking ability and other neurological functions to assess potential improvements.
A vizsgálat csoportja
- Open label stem cell armA vizsgált kezelés
The first 5 participants will receive 4 intrathecal injections of c-Kit stem cells at a dose of 25 x 106 cells per injection. The next 5 patients will receive 4 intrathecal injections of c-Kit stem cells at a dose of 50 x 106cells per injection. The next 10 patients will receive 4 intrathecal injections of c-Kit stem cells at a dose of 80 x 106cells per injection. Only if a dose is deemed safe by the investigators after 1 month of its first injection, will we advance to the next dose.
Kezelés: Amniotic fluid or placental CD117 stem cells
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I/II Trial of Intrathecal Delivery of Amniotic Fluid Stem Cells for Primary and Secondary Progressive Multiple Sclerosis
- A regiszteradat frissítve
- 2026. február 6.